Clinical Trials Logo

Corneal Ectasia clinical trials

View clinical trials related to Corneal Ectasia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06347900 Recruiting - Corneal Ectasia Clinical Trials

Corneal Topographic Changes in Different Grades of OSA

Start date: January 1, 2024
Phase:
Study type: Observational

Corneal topographic parameters in different degrees of obstructive sleep apnea

NCT ID: NCT05027295 Recruiting - Keratoconus Clinical Trials

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

Start date: July 30, 2021
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

NCT ID: NCT04905108 Recruiting - Keratoconus Clinical Trials

Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia

Start date: June 2, 2021
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery and improved patient comfort in the early postoperative healing period.

NCT ID: NCT04897503 Recruiting - Keratoconus Clinical Trials

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

CXL
Start date: April 16, 2021
Phase: Phase 3
Study type: Interventional

This study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.

NCT ID: NCT04401865 Recruiting - Keratoconus Clinical Trials

Safety and Effectiveness of the PXL-Platinum 330 System

Start date: June 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.

NCT ID: NCT04251143 Recruiting - Keratoconus Clinical Trials

Dresden Corneal Disease and Treatment Study

Start date: March 12, 2018
Phase:
Study type: Observational

The purpose of this study is long-term follow up of patients with corneal diseases to analyze the quality of surgical interventions and diagnosis. Corneal ectasia, especially keratoconus, is a corneal disease that leads to an irreversible loss of visual acuity while the cornea becomes steeper, thinner and irregular. For these patients, surgical intervention (e.g. corneal cross-linking) is performed, in case of disease progression. Overall, a long-term follow up is needed to evaluate an early disease progression as well as corneal stability after surgical intervention.

NCT ID: NCT04094090 Recruiting - Keratoconus Clinical Trials

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

Start date: October 19, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.

NCT ID: NCT03319082 Recruiting - Corneal Ectasia Clinical Trials

Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery

CXL
Start date: October 4, 2017
Phase:
Study type: Observational [Patient Registry]

The objectives of this post market registry are to evaluate the safety and durability of treatment effect up to 3 years following cross-linking performed with Photrexa Viscous (riboflavin 5'- phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'- phosphate ophthalmic solution), and the KXL System in patients with corneal ectasia following refractive surgery.

NCT ID: NCT02009709 Recruiting - Keratoconus Clinical Trials

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

Start date: October 2013
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the effectiveness and safety of corneal collagen cross-linking at irradiance levels of 9 and 18 mW/cm2.

NCT ID: NCT01325298 Recruiting - Keratoconus Clinical Trials

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

Start date: March 2011
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate two different ultraviolet (UV) dosing regimens for corneal collagen cross linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive surgery ectasia.